ATE200778T1 - 1-biphenylimidazolderivate, verfahren zu deren herstellung und deren therapeutische anwendung - Google Patents

1-biphenylimidazolderivate, verfahren zu deren herstellung und deren therapeutische anwendung

Info

Publication number
ATE200778T1
ATE200778T1 AT93200195T AT93200195T ATE200778T1 AT E200778 T1 ATE200778 T1 AT E200778T1 AT 93200195 T AT93200195 T AT 93200195T AT 93200195 T AT93200195 T AT 93200195T AT E200778 T1 ATE200778 T1 AT E200778T1
Authority
AT
Austria
Prior art keywords
alkyl
aryl
alkoxy
substd
halo
Prior art date
Application number
AT93200195T
Other languages
English (en)
Inventor
Hiroaki Yanagisawa
Yasuo Shimoji
Koichi Fujimoto
Takuro Kanazaki
Yoshiya Amemiya
Hiroyuki Koike
Toshio Sada
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27549327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE200778(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE200778T1 publication Critical patent/ATE200778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT93200195T 1991-02-21 1992-02-21 1-biphenylimidazolderivate, verfahren zu deren herstellung und deren therapeutische anwendung ATE200778T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2709891 1991-02-21
JP9658891 1991-04-26
JP13488991 1991-06-06
JP16713891 1991-07-08
JP17397291 1991-07-15
JP18484191 1991-07-24

Publications (1)

Publication Number Publication Date
ATE200778T1 true ATE200778T1 (de) 2001-05-15

Family

ID=27549327

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92301449T ATE200777T1 (de) 1991-02-21 1992-02-21 1-biphenylimidazolderivate, verfahren zu deren herstellung und deren therapeutische anwendung
AT93200195T ATE200778T1 (de) 1991-02-21 1992-02-21 1-biphenylimidazolderivate, verfahren zu deren herstellung und deren therapeutische anwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92301449T ATE200777T1 (de) 1991-02-21 1992-02-21 1-biphenylimidazolderivate, verfahren zu deren herstellung und deren therapeutische anwendung

Country Status (22)

Country Link
EP (2) EP0503785B3 (de)
JP (1) JPH07121918B2 (de)
KR (1) KR0128289B1 (de)
CN (3) CN1045770C (de)
AT (2) ATE200777T1 (de)
CA (2) CA2061607C (de)
CZ (1) CZ289194B6 (de)
DE (6) DE122005000051I1 (de)
DK (2) DK0545912T3 (de)
ES (2) ES2157895T7 (de)
FI (2) FI112942B3 (de)
GR (2) GR3035906T3 (de)
HU (3) HU223338B1 (de)
IE (1) IE920540A1 (de)
IL (3) IL101034A (de)
IS (1) IS1756B (de)
LU (4) LU91056I2 (de)
NL (3) NL300133I2 (de)
NO (6) NO304516B3 (de)
NZ (1) NZ241681A (de)
PT (2) PT545912E (de)
RU (1) RU2128173C1 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
DE69329982T2 (de) * 1992-06-02 2001-09-27 Sankyo Co., Ltd. 4-Carboxyimidazolderivate als Angiotensin-II-Antagonisten und ihre therapeutische Verwendung
CA2111662C (en) * 1992-12-17 2004-11-23 Hiroaki Yanagisawa Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
ATE206050T1 (de) * 1994-03-16 2001-10-15 Sankyo Co Okulares hypotensium
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AUPN786896A0 (en) 1996-02-02 1996-02-29 Telstra Corporation Limited A network fault system
CN1221259C (zh) * 1996-07-15 2005-10-05 三共株式会社 Cs－866、氯沙坦和坎迪沙坦用于制备治疗动脉硬化的药物
AU5576498A (en) * 1997-02-05 1998-08-26 Sankyo Company Limited Prophylactic or therapeutic agent for diabetic complication
USD441509S1 (en) 1997-08-25 2001-05-01 Mastrad S.A. Combined hand cleaner and hand cleaner base
AU141230S (en) 1999-02-26 2000-07-25 Unilever Plc Detergent tablet
WO2000078727A1 (en) * 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Process for the preparation of imidazole derivatives
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4521844B2 (ja) * 2000-04-18 2010-08-11 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
CA2420844A1 (en) * 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1595540A1 (de) * 2000-11-21 2005-11-16 Sankyo Company Limited Zusammensetzung enthaltend einen Angiotensin-II-Rezeptor-Antagonist und einen Diuretikum und deren Verwendung zur Behandlung von Bluthochdruck
WO2003020315A1 (fr) * 2001-08-28 2003-03-13 Sankyo Company, Limited Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
CN1197866C (zh) * 2003-03-21 2005-04-20 上海医药工业研究院 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法
JP4489020B2 (ja) 2003-04-15 2010-06-23 第一三共株式会社 眼内血管新生性疾患の予防又は治療のための医薬
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
JP4511550B2 (ja) * 2004-09-02 2010-07-28 テバ ファーマシューティカル インダストリーズ リミティド オルメサルタンメドキソミルの調製法
BRPI0516128A (pt) 2004-10-08 2008-08-26 Novartis Ag uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
MX2007005129A (es) 2004-10-27 2007-09-11 Daiichi Sankyo Co Ltd Compuesto de benceno que tiene 2 o mas sustituyentes.
CA2591694A1 (en) * 2004-12-30 2006-07-13 Teva Pharmaceutical Industries Ltd. Process for preparing olmesartan medoxomil at ph higher than 2.5
KR20090108739A (ko) * 2005-01-03 2009-10-16 테바 파마슈티컬 인더스트리즈 리미티드 불순물의 양이 감소된 올메사탄 메독소밀
JP5051897B2 (ja) * 2005-04-22 2012-10-17 第一三共株式会社 骨代謝性疾患の予防又は治療のための医薬
CA2616466A1 (en) * 2005-07-29 2007-02-15 Krka Process for the preparation of olmesartan medoxomil
EP1816131A1 (de) * 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung von Olmesartan Medoxomil
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
CZ299902B6 (cs) * 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
EP1801111B1 (de) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Polymorphe Formen von Olmesartan Medoxomil
CA2642988C (en) 2006-02-27 2015-10-27 Takeda Pharmaceutical Company Limited Pharmaceutical product comprising a benzimidazole in combination with a desiccant
EP1891952B1 (de) 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Pharmazeutische Zusammensetzung mit Olmesartan-Medoxomil
WO2007148344A2 (en) * 2006-06-19 2007-12-27 Matrix Laboratories Limited Process for the preparation of olmesartan medoxomil
EP1988091B1 (de) 2007-02-07 2015-06-10 Kyowa Hakko Kirin Co., Ltd. Trizyklische verbindungen
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2141160A4 (de) * 2007-03-23 2011-06-29 Daiichi Sankyo Co Ltd Zerriebener kristall von olmesartanmedoxomil
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101311168B (zh) * 2007-05-21 2010-12-08 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
CN101311169B (zh) * 2007-05-21 2011-03-16 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0710680D0 (en) * 2007-06-05 2007-07-11 Generics Uk Ltd Novel crystalline form of olmesartan medoxmil
EP2174666B1 (de) * 2007-06-22 2013-12-18 Daiichi Sankyo Company, Limited Medizinisches mittel zur behandlung von amyloid beta-induzierten störungen der cerebralen zirkulation oder des cerebralen blutflusses
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN102083823B (zh) 2008-06-09 2015-10-07 第一三共株式会社 1-联苯甲基咪唑化合物的制备方法
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
JP5559689B2 (ja) 2008-08-06 2014-07-23 協和発酵キリン株式会社 ３環系化合物
JP5395908B2 (ja) 2008-11-17 2014-01-22 浙江海正薬業股▲ふん▼有限公司 ４−（１−ヒドロキシ−１−メチルエチル）−２−プロピルイミダゾール−５−カルボン酸エステルの製造方法
JP2009102340A (ja) * 2008-12-04 2009-05-14 Daiichi Sankyo Co Ltd イミダゾール誘導体の製造法（２）
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
SG175296A1 (en) 2009-04-28 2011-11-28 Daiichi Sankyo Co Ltd Novel solvate crystals
WO2010126013A1 (ja) 2009-04-28 2010-11-04 第一三共株式会社 オルメサルタンメドキソミルの製造方法
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
CN102050816A (zh) * 2009-10-28 2011-05-11 北京万全阳光医学技术有限公司 一种合成奥美沙坦酯的方法
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
WO2011083112A2 (en) 2010-01-05 2011-07-14 Ratiopharm Gmbh Solid oral dosage form containing olmesartan medoxomil
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
JP5137996B2 (ja) * 2010-04-28 2013-02-06 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
EP2425859A1 (de) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulationen von Olmesartan
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102206208A (zh) * 2010-12-24 2011-10-05 上海现代制药股份有限公司 含低水平杂质的奥美沙坦酯的制备方法
CN102060778B (zh) * 2010-12-24 2012-05-23 江苏江神药物化学有限公司 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
KR20140051998A (ko) 2011-08-03 2014-05-02 교와 핫꼬 기린 가부시키가이샤 디벤조옥세핀 유도체
WO2013090196A1 (en) 2011-12-15 2013-06-20 Takeda Pharmaceuticals U.S.A., Inc. Combinations of azilsartan and chlorthalidone for treating hypertension black patients
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
CN104583185A (zh) 2012-08-31 2015-04-29 株式会社Api 联芳基化合物的制造方法
IN2015DN02241A (de) 2012-09-26 2015-08-21 Api Corp
JP6218084B2 (ja) 2012-10-04 2017-10-25 国立研究開発法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN103044407A (zh) * 2012-12-20 2013-04-17 安徽悦康凯悦制药有限公司 奥美沙坦酯的制备方法
CN103965167A (zh) * 2013-01-29 2014-08-06 通化济达医药有限公司 咪唑羧酸衍生物
JP2014152127A (ja) * 2013-02-06 2014-08-25 Tokuyama Corp オルメサルタンメドキソミルの製造方法
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP3025711B1 (de) 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medikament zur vorbeugung oder behandlung von hypertonie
CN103880825B (zh) * 2014-03-14 2019-03-05 浙江华海药业股份有限公司 一种高纯的三苯甲基奥美沙坦酯的制备工艺
CN104356069B (zh) * 2014-11-18 2016-09-14 黄冈鲁班药业有限公司 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用
CN104447564B (zh) * 2014-11-24 2016-08-31 广州天赐高新材料股份有限公司 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法
CN104402873A (zh) * 2014-12-02 2015-03-11 千辉药业（安徽）有限责任公司 一种奥美沙坦酯中间体的制备方法
CN105481842A (zh) * 2015-12-15 2016-04-13 江苏中邦制药有限公司 一种奥美沙坦酯的制备方法
CN108778334A (zh) 2016-03-24 2018-11-09 第三共株式会社 用于治疗肾脏疾病的药物
CN106749195A (zh) * 2016-12-30 2017-05-31 青岛黄海制药有限责任公司 一种奥美沙坦酯中间体杂质合成、鉴定的方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN109081812B (zh) * 2018-08-30 2022-08-16 黄冈鲁班药业股份有限公司 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
CA2016710A1 (en) 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
WO1991012002A1 (en) 1990-02-13 1991-08-22 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
US5140037A (en) 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
CA2061607A1 (en) 1992-08-22
PT503785E (pt) 2001-08-30
NL300227I1 (nl) 2006-06-01
RU2128173C1 (ru) 1999-03-27
EP0503785B1 (de) 2001-04-25
EP0545912A2 (de) 1993-06-09
IL101034A (en) 1996-10-16
ATE200777T1 (de) 2001-05-15
DE10299043I1 (de) 2003-03-27
NL300375I1 (nl) 2009-04-01
NO304516B1 (no) 1999-01-04
EP0503785B3 (de) 2012-02-29
LU91056I2 (fr) 2004-10-19
HU211934A9 (en) 1996-01-29
CZ289194B6 (cs) 2001-11-14
DE69231801D1 (de) 2001-05-31
NO304517B1 (no) 1999-01-04
RU95101430A (ru) 1997-02-20
CN1065063A (zh) 1992-10-07
DK0545912T3 (da) 2001-06-18
NO954507D0 (no) 1995-11-09
CN1189490A (zh) 1998-08-05
PT545912E (pt) 2001-08-30
FI112942B (fi) 2004-02-13
HU9601179D0 (en) 1996-07-29
DE69231798T3 (de) 2012-07-12
CA2061607C (en) 1999-01-19
NO920688L (no) 1992-08-24
KR920016429A (ko) 1992-09-24
LU91847I2 (fr) 2011-09-26
LU91571I2 (fr) 2009-07-13
NL300133I1 (nl) 2003-10-01
HUT60475A (en) 1992-09-28
NO304516B3 (no) 2012-06-11
FI955248A0 (fi) 1995-11-02
IE970752A1 (en) 2000-02-23
HU223667B1 (hu) 2004-11-29
DE69231798D1 (de) 2001-05-31
FI920749A7 (fi) 1992-08-22
NO2011013I1 (no) 2011-08-22
FI955248A7 (fi) 1995-11-02
DE10299043I2 (de) 2003-08-07
CN1121859C (zh) 2003-09-24
CN1045770C (zh) 1999-10-20
CN1101384C (zh) 2003-02-12
ES2156866T3 (es) 2001-08-01
NO920688D0 (no) 1992-02-21
DE69231798T2 (de) 2001-12-06
FI920749A0 (fi) 1992-02-20
EP0503785A1 (de) 1992-09-16
NO2006012I1 (no) 2006-10-30
GR3035909T3 (en) 2001-08-31
HK1011969A1 (en) 1999-07-23
IL114996A (en) 1997-07-13
KR0128289B1 (ko) 1998-04-02
JPH0578328A (ja) 1993-03-30
DE122011000011I1 (de) 2011-06-16
AU1112592A (en) 1992-08-27
GR3035906T3 (en) 2001-08-31
NO954507L (no) 1992-08-24
NZ241681A (en) 1993-07-27
CA2229000C (en) 2002-04-09
HU9200578D0 (en) 1992-05-28
EP0545912B1 (de) 2001-04-25
CZ51692A3 (en) 1993-03-17
IL114996A0 (en) 1995-12-08
FI112941B (fi) 2004-02-13
CN1188645A (zh) 1998-07-29
JPH07121918B2 (ja) 1995-12-25
LU91330I2 (fr) 2007-06-04
NO2003009I2 (en) 2007-12-11
EP0545912A3 (de) 1993-06-16
AU647887B2 (en) 1994-03-31
NL300133I2 (nl) 2004-03-01
DE122005000051I1 (de) 2006-01-26
ES2157895T3 (es) 2001-09-01
DE122009000024I1 (de) 2009-09-17
IE920540A1 (en) 1992-08-26
FI112942B3 (fi) 2012-03-13
IS3819A (is) 1992-08-22
DE69231801T2 (de) 2001-12-06
HU223338B1 (hu) 2004-06-28
CA2229000A1 (en) 1992-08-22
IL101034A0 (en) 1992-11-15
NO2009019I1 (no) 2009-09-21
ES2157895T7 (es) 2012-06-14
IS1756B (is) 2000-12-28
HK1011361A1 (en) 1999-07-09
DK0503785T3 (da) 2001-06-18

Similar Documents

Publication Publication Date Title
ATE200777T1 (de) 1-biphenylimidazolderivate, verfahren zu deren herstellung und deren therapeutische anwendung
DK78995A (da) Anvendelse af visse substituerede arylalkylaminer til fremstilling af et lægemiddel med neurobeskyttende virkning
ES8602012A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-azaciclos alquiltiopenen.
ATE192155T1 (de) Tetracyclische 1,4-oxazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE3870486D1 (de) 1-(1-aryl-2-hydroxy-ethyl)-imidazole und deren salze, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung.
MEP20308A (en) THE USE OF R(+)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
HUT60742A (en) Method for producing imidqzo-benzodiazepine-2-(1h)-one derivatives and pharmaceutical preparatives containing them

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner